Tissium receives FDA authorization for suture-free nerve repair system
Tissium, a Paris-based medical technology company founded on MIT research, has secured De Novo marketing authorization from the U.S. Food and Drug Administration for its non-traumatic peripheral nerve repair platform. The clearance enables commercialization of its first product, which uses a flexible, biocompatible polymer that bonds to wet tissue when activated by blue light. In a recent clinical trial of 12 patients, all of whom completed follow-up, regained full flexion and extension of their injured digits, and reported no pain 12 months after surgery.










